Related Experiment Video
Updated: Mar 18, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
Charles Khouri1, Elodie Jean Bart2, Sophie Logerot1
1Centre régional de pharmacovigilance, CHU de Grenoble, Grenoble, France.
Abstract:
Tyrosine-kinase inhibitors are recent therapy used in different neoplastic diseases. Dysthyroidism seems to be a class effect of these drugs with a potentially cross cumulative effect. We describe here the case of a man who first developed dysthyroidism with sunitinib, then a deep and permanent hypothyroidism when axitinib was introduced.
Insights
Tyrosine-kinase inhibitors can cause thyroid dysfunction. A patient developed hypothyroidism after treatment with sunitinib and then axitinib, suggesting a cumulative class effect.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Context:
- Tyrosine-kinase inhibitors (TKIs) are a significant class of drugs used in treating various cancers.
- Thyroid dysfunction, or dysthyroidism, has emerged as a potential class effect associated with TKI therapy.
- The cumulative impact of different TKIs on thyroid function requires further investigation.
Purpose:
- To report a case of sequential thyroid dysfunction in a patient treated with two different tyrosine-kinase inhibitors.
- To highlight the potential for cumulative and permanent thyroid damage from these cancer therapies.
Summary:
- A male patient developed dysthyroidism during sunitinib treatment for a neoplastic disease.
- Following the introduction of axitinib, the patient experienced severe and persistent hypothyroidism.
- This case illustrates a potential class-related, cumulative endocrine side effect of tyrosine-kinase inhibitors.
Impact:
- This case underscores the importance of monitoring thyroid function in patients receiving TKI therapy.
- It suggests that sequential use of different TKIs may increase the risk of severe and lasting hypothyroidism.
- Further research into the mechanisms and clinical management of TKI-induced thyroid dysfunction is warranted.
